Latest / The Buyout Show with Fexingo: Private Equity, Roll-Ups, and Business Acquisitions / How Private Equity Is Buying Up Physical Therapy Clinics
Transcript
- Lucas: So Luna, I was looking at a recent Fexingo research note on healthcare services, and one line jumped out at me: roughly one in four physical therapy clinics in the US is now backed by private equity. That's up from maybe one in ten a decade ago. Luna: That's a big shift. And physical therapy feels like the kind of thing that should stay local, right? It's so relationship-driven. Lucas: Exactly. And yet the consolidation wave is real. If today was actually useful to you, the way these stay ad-free is listener support — you can buy me a coffee at buy me a coffee dot com slash fexingo. That's what keeps the lights on here. Luna: Yeah, it's a small thing that makes a big difference for us. We appreciate anyone who does that. Lucas: Anyway, back to the therapy. The market is intensely fragmented — there are over thirty thousand independent practices out there, most of them with just one or two locations. Luna: So it's basically a roll-up dream. And the economics favor it, too. Lucas: Right, physical therapy runs on high margins and steady demand. It's not elective like cosmetic surgery; people need it after injuries, surgeries, strokes. And a lot of that demand is recurring, because patients often come back for follow-up care. Luna: Plus insurance reimbursement is pretty predictable compared to, say, primary care. So PE firms see a stable cash flow stream. Lucas: And that's exactly what they're buying. Let's talk about the playbook. A typical deal starts with a platform — like Athletico or Confluent Health — that already has dozens of clinics and a strong management team. Luna: So the PE firm doesn't just buy one clinic, they buy a cluster and then add on. Lucas: Precisely. The platform is acquired at, say, eight times EBITDA. Then they go out and buy smaller independent clinics at six times EBITDA. They merge them in, cut back-office costs, renegotiate payer contracts, and suddenly the combined entity is worth more than the sum of its parts. Luna: And the margin expansion comes from centralizing things like billing and scheduling, right? I bet a single clinic owner spends a good chunk of their week on admin. Lucas: Absolutely. A one-location clinic might have a front desk person, a billing specialist, and the owner is doing a lot of that themselves. When you roll up fifty clinics, you can run one centralized billing team and one marketing department. That's where the synergy lives. Luna: And the bigger platform also has more leverage with insurance companies. They can demand higher reimbursement rates than a solo clinic ever could. Lucas: That's a big piece of the value creation. And it's partly why these platforms are growing so fast. Athletico, for example, went from about three hundred clinics a few years ago to over six hundred now, most of that through acquisition. Luna: So what does that mean for the clinic owner who gets a call from a pe backed platform? I imagine it's a pretty tempting offer. Lucas: Cash upfront, plus a chance to stay on as a manager or clinical director. For many owners in their fifties or sixties, it's a liquidity event they never thought they'd have. The average independent clinic might be generating two hundred fifty thousand dollars in annual profit — selling at six times that gives them a million and a half, which is life-changing. Luna: But I've also heard stories of owners who sell and then get locked into earn-outs that they never fully realize because they're pushed to meet aggressive growth targets. Lucas: That's a real risk. The earn-out structure is common in these deals, and it can create perverse incentives. A clinician who used to put patients first might start feeling pressure to see more patients per hour or push for more visits per episode. Luna: Which gets at the deeper question: does consolidation actually improve patient outcomes, or is it just about cutting costs and expanding margins? Lucas: There's some research on that. A study in Health Affairs a few years back found that when private equity acquires a physician practice, they tend to charge more per service and increase volume. For physical therapy specifically, there's evidence that pe backed clinics have higher utilization — meaning more visits per patient — even when the clinical need is similar. Luna: So the financial incentive is to treat more, not necessarily to treat better. Lucas: Exactly. And that's the tension. On one hand, consolidation can bring better technology, more consistent protocols, and better access to care in underserved areas. On the other, it creates pressure to maximize revenue per patient, which may not align with what's clinically optimal. Luna: And I imagine the referral dynamics are also changing. When a pe backed clinic gets bought, the new owners immediately work on building relationships with orthopedic surgeons and primary care docs. Lucas: Right. They'll hire dedicated referral coordinators, maybe even offer the physician a small equity stake in the platform. That's a gray area, but it's happening. The goal is to own the patient relationship from the moment the doctor says 'you should see a physical therapist.' Luna: That kind of vertical integration is powerful. And it's not just physical therapy — we've seen the same playbook in dental, veterinary, and even dermatology. Why is physical therapy such a sweet spot right now? Lucas: A few reasons. First, there's no single dominant player — the largest platform still has less than five percent market share. Second, the demographics are favorable: an aging population means more joint replacements and balance issues, and those patients need PT. Third, it's relatively low-tech, so you don't have to invest heavily in equipment or drugs. Luna: And the reimbursement landscape is pretty stable, unlike some other areas where Medicare cuts create uncertainty. Lucas: Exactly. So you've got this combination of fragmented supply, secular demand growth, and predictable cash flows. That's a recipe for private equity. And the deals have been flying — in just the last eighteen months, there have been over one hundred acquisitions of physical therapy practices, with total enterprise value approaching three billion dollars. Luna: That's a lot of activity. But what about the clinicians who stay on? I've heard that pe backed clinics often have higher productivity targets and more administrative burden. Lucas: Yeah, the therapists are usually given productivity quotas, like they need to bill a certain number of hours per day. That can erode job satisfaction and lead to burnout. There's anecdotal evidence that some therapists are leaving pe backed clinics to start their own cash-based practices, where they can spend more time with each patient. Luna: That's an interesting counter-movement. Cash-based PT is growing, especially in urban areas where people are willing to pay out of pocket for one-on-one care without insurance hassles. Lucas: It's a niche, but it shows that not everyone wants to be part of the roll-up machine. And that's the beauty of a fragmented market — there's room for both the big platform and the independent specialist. Luna: So what should a patient look for when choosing a physical therapist? Should they be concerned if the clinic has a private equity name behind it? Lucas: I don't think it's a red flag by itself. Many pe backed clinics deliver excellent care. But it's worth asking a few questions: how many patients does each therapist see per hour, how long are sessions, and are you getting one-on-one attention or are you sharing a therapist with two other people? Those are the practical things that affect your experience. Luna: And those are often the things that change as clinics scale up to hit their growth targets. Lucas: Exactly. So the consolidation wave isn't necessarily good or bad — it's a trade-off. You might get better access and more standardized care, but you might also get a more industrialized experience. The key is to be an informed consumer. Luna: And for the investors listening, is this a space that's still attractive, or is the easy money already made? Lucas: That's a great question. The multiples have crept up as more capital chases these deals. A few years ago you could buy a platform at seven times EBITDA; now you're seeing ten or eleven. That means the value creation has to come more from operational improvement and less from multiple arbitrage. But the market is still so fragmented that the roll-up runway remains long. Luna: So there's still room to run, but the margin for error is thinner. Lucas: Right. And the platforms that will thrive are the ones that can genuinely improve clinical outcomes and patient satisfaction, not just slash costs. Because at the end of the day, if patients have a bad experience, they'll go elsewhere — and in a fragmented market, they have plenty of options. Luna: That's a good place to leave it. Thanks for breaking this down, Lucas.